Ilaprazole (sodium hydrate)

Ilaprazole (IY-81149) sodium hydrate is an orally active proton pump inhibitor. Ilaprazole sodium hydrate irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor[1][2].

Product Specifications

CAS Number

[2322264-11-7]

Product Name Alternative

IY-81149 (sodium hydrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Proton Pump; TOPK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ilaprazole-sodium-hydrate.html

Purity

99.15

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=C(OC)C=CN=C1CS(C2=NC3=CC(N4C=CC=C4)=CC=C3[N-]2)=O.[Na+]

Molecular Formula

C19H21N4NaO4S

Molecular Weight

424.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Kwon D, et al. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo. Arzneimittelforschung. 2001;51 (3) :204-213. |[2]Zheng M, et al. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2017;8 (24) :39143-39153.